Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
OPEC chief stresses energy cooperation with China'Art Film' series launched to celebrate filmmaking and masterpiecesExhibition unveils rare masterpiece by ancient Chinese artistIn North Macedonia, two inmates walked out of hospital. Now, police are accused of helping themAssange faces further wait for appeal against extradition to USNation aims to create over 12 million new jobsShanghai released 2024 events guideOver 1.1M people in Gaza facing food insecurity: UNUN suspends nightA technicolor twist on Yu the Great
2.6535s , 6490.9375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Stellar Spectacle news portal